Rapid detection and differentiation of antibodies to HIV-1 and HIV-2 using multivalent antigens and magnetic immunochromatography testing.
A simplified lateral-flow assay for the detection of antibodies to HIV using magnetic-bead conjugates and multibranched peptides from both HIV-1 and HIV-2 was developed. Magnetic immunochromatography testing (MICT) uses a standard lateral-flow platform that incorporates magnetic-bead conjugates for quantitative measurement of the magnetic field distortion associated with the bound magnetic conjugate (reported as adjusted relative magnetic units [MAR]). The results of the optimized MICT assay were compared to standard enzyme immunoassay (EIA) and Western blotting (WB) results using a blinded 649-member panel of specimens from the United States, Cameroon, and West Africa. The panel was comprised of samples from individuals infected with various HIV-1 subtypes (n = 234) or HIV-2 (n = 65) and HIV-seronegative specimens (n = 350). Additionally, 13 HIV-1 seroconversion panels (total specimens = 85), a worldwide panel containing seven of the major circulating HIV-1 subtypes (n = 18), an HIV-2 panel, an HIV-1/HIV-2 mixed panel, and 100 prospective specimens were tested with completely concordant results. Assay reproducibility (observed MAR) for both intra- and interrun testing was excellent, with coefficients of variation of <12%. MICT can provide a rapid, low-cost method of determining HIV antibody status requiring no subjective interpretations.
Granade
Timothy C
TC
Centers for Disease Control and Prevention, 1600 Clifton Rd. NE, Mailstop A-25, Atlanta, GA 30333, USA. TGranade@cdc.gov
Workman
Shon
S
Wells
Susan K
SK
Holder
Angela N
AN
Owen
S Michele
SM
Pau
Chou-Pong
CP
D015492:AIDS Serodiagnosis; D000918:Antibody Specificity; D002845:Chromatography / Q000379:methods; D015483:HIV Antibodies / Q000097:blood*; D015488:HIV Antigens / Q000737:chemistry / Q000276:immunology*; D015658:HIV Infections / Q000175:diagnosis* / Q000276:immunology / Q000821:virology; D015497:HIV-1 / Q000276:immunology*; D015498:HIV-2 / Q000276:immunology*; D018189:Immunomagnetic Separation / Q000379:methods; D010455:Peptides / Q000276:immunology; D013997:Time Factors
D015483:HIV Antibodies; D015488:HIV Antigens; D010455:Peptides
J Clin Microbiol. 1998 Aug;36(8):2235-9
9665998
Eur J Clin Microbiol Infect Dis. 2001 Feb;20(2):104-10
11305462
J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):218-24
16394855
J Virol Methods. 1998 Nov;75(1):27-38
9820572
J Immunol Methods. 2007 Jan 10;318(1-2):59-64
17169369
J Virol Methods. 2000 Jun;87(1-2):63-70
10856753
Clin Diagn Lab Immunol. 2000 Jul;7(4):698-9
10882675
Indian J Med Res. 2005 Apr;121(4):510-8
15817960
J Acquir Immune Defic Syndr. 2007 Apr 1;44(4):484-8
17211281
J Clin Virol. 2004 Jul;30(3):229-32
15135740
Transfusion. 1992 Jul-Aug;32(6):548-53
1323886
AIDS. 2006 Aug 1;20(12):1655-60
16868447
Clin Diagn Lab Immunol. 2005 Jul;12(7):855-60
16002635
J Virol Methods. 2009 Sep;160(1-2):14-21
19482361
AIDS. 1993 Jun;7(6):883-5
8395857
J Hum Virol. 1997 Nov-Dec;1(1):45-51
10195230
MMWR Morb Mortal Wkly Rep. 2008 Jun 20;57(24):660-5
18566566
AIDS Res Hum Retroviruses. 2007 Dec;23(12):1491-8
18160006
Expert Rev Mol Diagn. 2007 Sep;7(5):499-505
17892358
AIDS. 1991 Jul;5(7):859-63
1892591
Trop Med Int Health. 2007 Feb;12(2):162-73
17300622
AIDS Res Ther. 2005 May 20;2(1):5
15907202
Curr HIV/AIDS Rep. 2006 Nov;3(4):169-75
17032576
J Immunol Methods. 2001 Nov 1;257(1-2):51-4
11687238